The Dutch and Swiss artificial intelligence startup in protein engineering, Cradle, recently announced the successful completion of a $73 million Series B financing round. This round was led by the investment firm IVP, and existing investors Index Ventures and Kindred Capital also participated in the financing. With this, Cradle's total financing amount has exceeded $100 million.

Cradle is dedicated to accelerating the research process of protein engineering through its artificial intelligence platform. The company states that this platform can simplify the development process of proteins, reduce costs, and thereby cut down the time and resources required by researchers when developing improved proteins. Such an efficient technological means can help scientific researchers obtain the desired results more quickly and promote the development of biotechnology.

With the arrival of this financing, Cradle plans to expand its wet laboratory facilities and further improve its machine learning system. The company has already established cooperative relationships with several renowned biotechnology companies, including Novo Nordisk and Ginkgo Bioworks. These collaborations have not only brought technological enhancements to Cradle but also provided broad prospects for the practical application of its products.

Protein engineering is an important field in life science research, with extensive applications in multiple industries such as medicine and agriculture. Cradle's innovative solutions are precisely designed to meet the growing demands in this field. Through intelligent means, Cradle hopes to make the development of proteins more efficient, thereby promoting the progress of biotechnology and facilitating the research and development of new drugs.

The founding team of Cradle said that they are full of confidence in future development and look forward to working with more partners to jointly promote the innovation of the biotechnology industry. With the financing in place, the company will accelerate its pace to commercialize its technology and assist global scientific researchers in achieving greater breakthroughs in the field of protein engineering.